NewGenIVF Assets Jump to US$32.7M, US$9.9M Profit on US$19.2M Acquisition Gain
NewGenIVF Group reported total assets of US$32.7 million as of December 31, 2025, up from US$3.6 million a year earlier. Net profit reached US$9.9 million, driven by a US$19.2 million bargain purchase gain from acquisitions of Nodexus, Microsort and cytometry IP, and the company authorized a US$2 million share buyback program.
1. Fiscal Year 2025 Financial Results
NewGenIVF Group closed fiscal 2025 with total assets of US$32.7 million, compared to US$3.6 million at year-end 2024, and recorded a net profit attributable to shareholders of US$9.9 million.
2. Acquisition Bargain Purchase Gains
In July 2025 the company completed acquisitions of Nodexus, Microsort and advanced cytometry intellectual property independently valued at US$17.9 million, generating a combined bargain purchase gain of US$19.2 million.
3. Share Repurchase and Diversification Strategy
In November 2025 the board authorized a US$2 million share repurchase program, while the firm advances its diversification through NewGenDigital’s digital asset innovation and NewGenSup’s health supplement initiatives.